Lupin launches Droxidopa capsules in the US

Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA

Lupin Limited announced the launch of Droxidopa capsules, 100 mg, 200 mg, and 300 mg, having received approval from the United States Food and Drug Administration U.S FDA. The product is manufactured at Lupin's facility in Nagpur, India.

Droxidopa capsules, 100 mg, 200 mg, and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA. It is indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to blackout" in adult patients with symptomatic neurogenic Orthostatic Hypotension (nOH). It is caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Droxidopa Capsules (RLD: Northera) had estimated annual sales of US $ 294 million in the U.S. (IQVIA MAT July 2021).